INTRAMUSCULAR HUMAN INTERFERON-β INJECTIONS IN TREATMENT OF CONDYLOMATA ACUMINATA

Alexander Schonfeld, Amihai Schattner, Madeleine Crespi, Hanoch Levavi, Jacob Shoham, Schmuel Nitke, David Wallach, Talia Hahn, Ovadia Yarden, Thomas Doerner, Michet Revel

Research output: Contribution to journalArticlepeer-review

137 Scopus citations

Abstract

A two-part study was done to assess the value of human fibroblast interferon (IFN-β) in the treatment of condylomata acuminata. The first part was an open study of different IFN-β preparations, which showed that intramuscular injection was the most suitable mode of administration of IFN-β. In the double-blind placebo section 22 patients were given injections of 2×106 units IFN-β or placebo for 10 consecutive days and followed up for 3 months. In 9 of the 11 in the IFN-β group and 2 in the placebo group lesions disappeared from about 5 weeks after completion of the course of injections. After 3 months 8 of the non-responders were given a course of IFN-β and all responded to treatment. None of those who had responded has had a recurrence, the disease-free period now being 12 months. Changes in (2'-5') oligo A synthetase levels in white blood cells confirm that intramuscular injections of IFN-β produce a systemic response.

Original languageEnglish
Pages (from-to)1038-1042
Number of pages5
JournalThe Lancet
Volume323
Issue number8385
DOIs
StatePublished - 12 May 1984
Externally publishedYes

Bibliographical note

Funding Information:
This work was supported by InterYeda Ltd, Israel.

Funding

This work was supported by InterYeda Ltd, Israel.

FundersFunder number
InterYeda Ltd

    Fingerprint

    Dive into the research topics of 'INTRAMUSCULAR HUMAN INTERFERON-β INJECTIONS IN TREATMENT OF CONDYLOMATA ACUMINATA'. Together they form a unique fingerprint.

    Cite this